Literature DB >> 21055682

Pathology of chronic hepatitis B and chronic hepatitis C.

M Isabel Fiel1.   

Abstract

Histologic evaluation of the liver is a major component in the medical management and treatment algorithm of patients with chronic hepatitis B (HBV) and chronic hepatitis C (HCV). Liver biopsy in these patients remains the gold standard, and decisions on treatment are often predicated on the degree of damage and stage of fibrosis. This article outlines the clinical course and serologic diagnosis of HBV and HCV for the clinician and the pathologist, who together have a close working relationship in managing patients with acute and chronic liver disease. The salient histologic features are elucidated in an attempt to provide the clinician with an understanding of the basic histopathology underlying chronic HCV and HBV.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21055682     DOI: 10.1016/j.cld.2010.07.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  10 in total

1.  An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.

Authors:  Siyuan Ma; Xiaohua Chen; Quanhui Tan; Dan Li; Shenglan Dai; Shanshan Wu; Yongsheng Yu; Guoqing Zang; Zhenghao Tang
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

Review 2.  What's new in hepatitis C virus infections in children?

Authors:  Malgorzata Pawlowska; Krzysztof Domagalski; Anna Pniewska; Beata Smok; Waldemar Halota; Andrzej Tretyn
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 3.  Is liver biopsy still needed in children with chronic viral hepatitis?

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Magdalena Pluta; Magdalena Marczyńska
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 4.  Liver pathology of hepatitis C, beyond grading and staging of the disease.

Authors:  Sadhna Dhingra; Stephen C Ward; Swan N Thung
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  Association of markers of chronic viral hepatitis and blood mercury levels in US reproductive-age women from NHANES 2001-2008: a cross-sectional study.

Authors:  Mary C Sheehan; Thomas A Burke; Patrick N Breysse; Ana Navas-Acien; John McGready; Mary A Fox
Journal:  Environ Health       Date:  2012-09-12       Impact factor: 5.984

6.  Humic acid inhibits HBV-induced autophagosome formation and induces apoptosis in HBV-transfected Hep G2 cells.

Authors:  Kishor Pant; Ajay K Yadav; Parul Gupta; Abhishek Singh Rathore; Baibaswata Nayak; Senthil K Venugopal
Journal:  Sci Rep       Date:  2016-10-06       Impact factor: 4.379

7.  Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression.

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Magdalena Pluta; Bożena Walewska-Zielecka; Magdalena Marczyńska
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

8.  Liver Graft MicroRNAs Expression in Different Etiology of Acute Jaundice after Living Donor Liver Transplantation.

Authors:  Shu-Hsien Lin; Kun-Ta Wu; Chih-Chi Wang; Kuang-Tzu Huang; Kuang-Den Chen; Li-Wen Hsu; Hock-Liew Eng; King-Wah Chiu
Journal:  Biology (Basel)       Date:  2022-08-17

9.  The influence of hepatitis B and C virus coinfection on liver histopathology in children.

Authors:  Maria Pokorska-Śpiewak; Barbara Kowalik-Mikołajewska; Małgorzata Aniszewska; Bożena Walewska-Zielecka; Magdalena Marczyńska
Journal:  Eur J Pediatr       Date:  2014-08-30       Impact factor: 3.183

10.  Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis.

Authors:  Mingjie Xie; Huiting Guo; Guohua Lou; Jiping Yao; Yanning Liu; Yi Sun; Zhenggang Yang; Min Zheng
Journal:  J Cell Mol Med       Date:  2020-12-02       Impact factor: 5.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.